Epgo23: Expected probability to do third phase III trial

In Sterniii3/drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Expected probability to do third phase III trial

Description

In the setting of Case 2: Strategy 2/2( + 1); at least two trials significant (and the treatment effect of the other one at least showing in the same direction) this function calculates the probability that a third phase III trial is necessary.

Usage

Epgo23(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2)

Arguments

HRgo	threshold value for the go/no-go decision rule
d2	total number of events in phase II
alpha	significance level
beta	1-beta power for calculation of sample size for phase III
w	weight for mixture prior distribution
hr1	first assumed true treatment effect on HR scale for prior distribution
hr2	second assumed true treatment effect on HR scale for prior distribution
id1	amount of information for hr1 in terms of number of events
id2	amount of information for hr2 in terms of number of events

Value

The output of the function Epgo23() is the probability to a third phase III trial.

Examples

res <- Epgo23(HRgo = 0.8, d2 = 50,  w = 0.3, alpha = 0.025, beta = 0.1,
                               hr1 =  0.69, hr2 = 0.81, id1 = 280, id2 = 420)

Sterniii3/drugdevelopR documentation built on Jan. 14, 2025, 7:50 p.m.